Balachandran Premalatha, Govindarajan Rajgopal
National Center for Natural Products Research, Department of Pharmacognosy, University of Mississippi, MS 38677, USA.
Pharmacol Res. 2005 Jan;51(1):19-30. doi: 10.1016/j.phrs.2004.04.010.
An integrated approach is needed to manage cancer using the growing body of knowledge gained through scientific developments. Thousands of herbal and traditional compounds are being screened worldwide to validate their use as anti-cancerous drugs. The science of Ayurveda is supposed to add a step on to the curative aspects of cancers that have resemblance with clinical entities of arbuda and granthi mentioned in Sushrutha samhita. Hence, an attempt is made in this review to discuss about the pathology and therapeutic management of various cancers described in Ayurveda. Review of literature on anticancer drugs of plant origin revealed identification of newer ayurvedic drugs that are not mentioned in the ancient texts. These new findings add up to ayurvedic science that has been developed through ages. In addition, details of experimental and clinical studies conducted on single and compound ayurvedic preparations for their anticancer efficacy strongly emphasize ayurvedic therapy as a scientifically driven one and not simply unconventional.
需要采用综合方法，利用通过科学发展积累的越来越多的知识来管理癌症。全球正在筛选数千种草药和传统化合物，以验证它们作为抗癌药物的用途。阿育吠陀科学应该在与《妙闻集》中提到的肿瘤和瘿瘤临床实体相似的癌症治疗方面更进一步。因此，本综述试图讨论阿育吠陀中描述的各种癌症的病理学和治疗管理。对植物源抗癌药物的文献综述揭示了一些古代文献中未提及的新阿育吠陀药物的鉴定。这些新发现丰富了历经岁月发展而来的阿育吠陀科学。此外，针对单一和复合阿育吠陀制剂的抗癌功效进行的实验和临床研究细节有力地强调了阿育吠陀疗法是基于科学的，而非仅仅是非常规疗法。
